- Report
- February 2024
- 70 Pages
Japan
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
United States
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
Spain
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
Iran
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
Australia
From €4196EUR$4,750USD£3,676GBP
- Report
- February 2024
- 70 Pages
China
From €4196EUR$4,750USD£3,676GBP
- Report
- August 2023
- 90 Pages
Global
From €4196EUR$4,750USD£3,676GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4196EUR$4,750USD£3,676GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4196EUR$4,750USD£3,676GBP
- Report
- October 2022
- 70 Pages
Africa
From €4196EUR$4,750USD£3,676GBP
- Report
- August 2023
- 150 Pages
North America
From €4196EUR$4,750USD£3,676GBP

Janumet is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It is a combination of two drugs, sitagliptin and metformin, which work together to lower blood sugar levels. Janumet is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. These drugs are used to help regulate hormones and metabolism, and can help improve quality of life for those with these conditions.
Some companies in the Janumet market include Merck & Co., Inc., AstraZeneca, and Boehringer Ingelheim. Show Less Read more